Navigation Links
Evalve Announces CE Mark Approval of the World's First Percutaneous Valve Repair System

MENLO PARK, Calif., March 25 /PRNewswire/ -- Evalve, Inc., the leader in the development of devices for the percutaneous repair of cardiac valves, announced today CE Mark approval for its MitraClip(R) system. The MitraClip is the first commercially available device which enables a non-surgical option for patients suffering from the effects of mitral regurgitation (MR).

MR is the most common type of heart valve insufficiency in the United States and the second most common in Europe, affecting millions of people worldwide. Both in the United States and Europe, the vast majority of patients are untreated, which leaves their hearts affected by the chronic volume overload caused by MR, requiring the heart to work harder, and ultimately leading to heart failure.

CE Mark approval gives Evalve the ability to train and educate physicians in Europe on the use of the MitraClip device increasing the number of patients who will potentially benefit from this innovative treatment. Evalve will work with hospitals across Europe to establish training programs which will allow physicians to gain access to this new technology.
In addition to CE Mark approval, company highlights include:

-- High Risk Registry Study Arm Enrollment Completed: Evalve recently

completed enrollment in the high-risk registry arm of the Endovascular

Valve Edge-to-Edge REpair STudy (EVEREST) in North America. Patients

who are high risk surgical candidates may benefit from a less invasive

procedure. Investigators are collecting follow-up data to assess the

risk-benefit profile from the less invasive percutaneous intervention

with the MitraClip device.

-- Continued Progress with EVEREST Trial: The EVEREST investigators from

more than 40 sites across North America have reached additional

milestones in the ongoing FDA-approved Phase II clinical study.

EVEREST Investigators have treated more than 300 patients with close

to 400 MitraClip devices implanted. Trial data continues to grow with

a significant amount of three-year follow up results available as well

as four-year data from some patients.

-- Presentation of MitraClip Procedure Results: Data regarding the

positive results in functional MR (ischemic and cardiomyopathy)

patients will be presented by James Hermiller, M.D., director of the

interventional fellowship program at St. Vincent Heart Center of

Indiana in Indianapolis, at the SCAI-ACCi2 annual meeting in Chicago

as part of the late-breaking clinical trial program on Tuesday,

April 1. In addition to the data presentation, Evalve is sponsoring a

breakfast symposium organized by SCAI on Monday, March 31 where

MitraClip device data will be reviewed. The "Understanding Mitral

Regurgitation" symposium is being chaired by Ted Feldman, M.D.,

national principal interventional cardiology investigator for the

EVEREST study.

"The progress we have made, notably the milestones achieved in the EVEREST trial and receiving CE Mark approval, are important as we move toward commercialization in Europe and the U.S.," said Ferolyn Powell, president and chief executive officer of Evalve. "We believe the MitraClip system has the potential to benefit patients who currently suffer from the serious effects of MR. Oftentimes patients in consultation with their doctors choose not to undergo surgical treatment because of the associated risks and trauma. However, until now surgery was the only available treatment option. The MitraClip offers the patients a new alternative."


EVEREST investigators are currently enrolling patients in the randomized arm of the study with the goal of completing enrollment by the end of 2008.
Enrollment in the study is open to several patient groups:

-- Patients with either degenerative or functional MR

-- Patients who are good surgical candidates and are open to the option

of a less invasive approach

-- Patients who are higher risk surgical candidates but are considered


More information about the EVEREST trial is available at

About the MitraClip Procedure

Percutaneous mitral repair with Evalve's MitraClip device is performed by interventional cardiologists in the catheterization laboratory. The heart beats normally during the procedure, and therefore does not require a heart-lung bypass machine. In addition to improving blood flow through the heart, the procedure may also relieve symptoms such as fatigue and shortness of breath that often affect patients with significant MR. After treatment, patients generally recover quickly. The MitraClip device may improve quality of life and may help MR patients avoid or delay surgery, having preserved surgical options (valve repair or replacement) should surgery become necessary.

About Evalve, Inc.

Evalve, Inc. (Menlo Park, Calif.) was incorporated in 1999 to design, develop, manufacture, and market innovate devices to enable percutaneous repair of cardiac valves. The company's initial products are intended to reduce the risks, trauma and costs associated with current open, arrested heart surgical options. The company's present development and clinical efforts are focused on mitral valve repair. For more information about Evalve, Inc., and for an animated explanation of the Percutaneous Mitral Repair procedure using the MitraClip device, visit Evalve is the first portfolio company from the medical device company incubator, The Foundry (

MitraClip and Evalve are registered trademarks of Evalve, Inc.

SOURCE Evalve, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Evalve(R) Completes $60 Million Series D Financing
2. UPDATED: Evalve(R) Completes $60 Million Series D Financing
3. Edwards Lifesciences Initiates Patent Infringement Litigation Against CoreValve in the U.S.
4. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
5. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. HEI, Inc. Announces Sale of RFID Division Assets
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
9. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
10. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
11. Brooke Franchise Corporation Announces Selected July Results
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article published November ... and the University of British Columbia suggested that laws requiring bicyclists to wear helmets ... that part of the reason for the controversial conclusion is that, while helmets have ...
(Date:11/27/2015)... ... November 27, 2015 , ... An inventor, from Hopkinsville, Ky., ... medications at home, so he invented the patent-pending ELECTRONIC M.D. , The ELECTRONIC ... In doing so, it could help to prevent potential overdose situations. As a ...
(Date:11/27/2015)... ... November 27, 2015 , ... ProSidebar: Fashion is a ... X. With ProSidebar: Fasion, video editors can easily add an informative sidebar to ... title opener. Utilize presets featuring self-animating drop zones, lines, bars, and text with ...
(Date:11/27/2015)... ... 27, 2015 , ... A simply groundbreaking television series, "Voices in America", which ... into an array of issues that are presently affecting Americans. Dedicated to providing the ... show is changing the subjects consumers focus on, one episode at a time. ...
(Date:11/27/2015)... ... 2015 , ... The men and women on this list ... the country. They have overseen financial turnarounds, shown commitment to their community through ... as a whole through their advocacy and professional efforts. , Becker's Hospital Review ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 2015  The total global healthcare industry is expected to ... Latin America has the highest projected growth ... Japan ), is second with growth projected at ... increased healthcare expenditure. In 2013-2014, total government funded healthcare was ... 2008-2009 to 41.2% in 2013-2014. In real terms, out of ...
(Date:11/25/2015)... , Nov. 25, 2015  The American ... and Gynecologists (ACOG), and the March of Dimes ... Protecting Our Infants Act of 2015 ... number of newborns born exposed to drugs, such ... the bill,s introduction, all three organizations have worked ...
(Date:11/25/2015)... AAIPharma Services Corp./Cambridge Major Laboratories, Inc. ... $15.8  Million to expand its laboratories and global ... The expansion will provide additional office space and ... of the pharmaceutical and biotechnology markets. ... up to 40,000 square feet of expanded development ...
Breaking Medicine Technology: